Psychometric Validation of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM)

por Brod, Meryl, Højby Rasmussen, Michael, Vad, Knud, Alolga, Suzanne, Bushnell, Donald M., Bedoin, Jacques, Maniatis, Aristides
Publicado 2021

Changes in Manufacturing Processes of Biologic Therapies Can Alter the Immunogenicity Profile of the Product

por Vanderlaan, Martin, Maniatis, Aristides, Olney, Robert, Rahmaoui, Abdelkader, Yau, Linda, Quarmby, Valerie, Azzolino, Craig, Woods, Cynthia, Moawad, Dalia
Publicado 2019

Psychometric Validation of the Growth Hormone Deficiency–Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency–Parent Treatment Burden Measure (GHD-PTB)

por Brod, Meryl, Rasmussen, Michael Højby, Alolga, Suzanne, Beck, Jane F., Bushnell, Donald M., Lee, Kai Wai, Maniatis, Aristides
Publicado 2022

SAT642 Effective Gh Replacement With Once-weekly Somapacitan In Children With Gh Deficiency: 2-year Results From Real4

por Miller, Bradley Scott, Blair, Joanne, Hojby, Michael, Maniatis, Aristides K, Mori, Jun, Boettcher, Volker, Kim, Ho-Seong, Bang, Rikke Beck, Polak, Michel, Horikawa, Reiko
Publicado 2023

Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH

por Miller, Bradley S, Blair, Joanne C, Rasmussen, Michael Højby, Maniatis, Aristides, Mori, Jun, Böttcher, Volker, Kim, Ho-Seong, Bang, Rikke Beck, Polak, Michel, Horikawa, Reiko
Publicado 2023

OR17-4 Transcon Growth Hormone In The Treatment Of Pediatric Growth Hormone Deficiency: Results Of The Phase 3 Height Trial

por Thornton, Paul, Hofman, Paul, Maniatis, Aristides, Aghajanova, Elena, Chertok, Elena, Korpal-Szczyrska, Maria, Giorgadze, Elene, Kovalenko, Tatiana, Shu, Aimee, Karpf, David, Beckert, Michael, Leff, Jonathan
Publicado 2019

Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”

por Miller, Bradley S, Blair, Joanne C, Rasmussen, Michael Højby, Maniatis, Aristides, Kildemoes, Rasmus Juul, Mori, Jun, Polak, Michel, Bang, Rikke Beck, Böttcher, Volker, Stagi, Stefano, Horikawa, Reiko
Publicado 2023

RF14 | LBMON195 Once-weekly Somapacitan Is Effective And Well Tolerated In Children With GH Deficiency: A Randomized Phase 3 Trial

por Miller, Bradley, Blair, Joanne C, Højby Rasmussen, Michael, Böttcher, Volker, Juul Kildemoes, Rasmus, Maniatis, Aristides, Beck Bang, Rikke, Mori, Jun, Polak, Michel, Stagi, Stefano, Horikawa, Reiko
Publicado 2022

Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial

por Miller, Bradley S, Blair, Joanne C, Rasmussen, Michael Højby, Maniatis, Aristides, Kildemoes, Rasmus Juul, Mori, Jun, Polak, Michel, Bang, Rikke Beck, Böttcher, Volker, Stagi, Stefano, Horikawa, Reiko
Publicado 2022

SAT643 Patient Preference Questionnaire Response After Switching To Somapacitan After Taking Daily Gh: 2-year Results From REAL4

por Blair, Joanne, Miller, Bradley Scott, Hojby, Michael, Maniatis, Aristides K, Mori, Jun, Boettcher, Volker, Kim, Ho-Seong, Bang, Rikke Beck, Fries Jensen, Lasse De, Polak, Michel, Horikawa, Reiko
Publicado 2023

THU173 Subanalysis By Tanner Stage In Phase 3 Trials In Children And Adolescents With Growth Hormone Deficiency Treated With Lonapegsomatropin

por Hofman, Paul, Thornton, Paul S, Nadgir, Ulhas M, Saenger, Paul, Chertok, Elena, Aghajanova, Elena M, Mao, Meng, Zhao, Carol, Ochoa-Maya, Margarita R, Komirenko, Allison, Shu, Aimee D, Maniatis, Aristides K
Publicado 2023

Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study

por Maniatis, Aristides K, Carakushansky, Mauri, Galcheva, Sonya, Prakasam, Gnanagurudasan, Fox, Larry A, Dankovcikova, Adriana, Loftus, Jane, Palladino, Andrew A, de los Angeles Resa, Maria, Turich Taylor, Carrie, Dattani, Mehul T, Lebl, Jan
Publicado 2022

PMON336 Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES): A multi-country, non-interventional, prospective, cohort study of patients receiving human growth hormone...

por Geffner, Mitchell E, Ibanez, Lourdes, Maniatis, Aristides, Torre, Daria L, Huang, Carol, Darendelieler, Feyza, Dattani, Mehul, Maghnie, Mohamad, Phillip, Moshe, Dahlgren, Jovanna, Horikawa, Reiko, Gomez, Roy, Kelly, Scott P, Wajnrajch, Michael P
Publicado 2022

Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency

por Maniatis, Aristides K, Casella, Samuel J, Nadgir, Ulhas M, Hofman, Paul, Saenger, Paul, Chertok, Elena, Aghajanova, Elena M, Song, Wenjie, Mao, Meng, Chessler, Steven D, Komirenko, Allison, Beckert, Michael, Shu, Aimee D, Thornton, Paul S
Publicado 2021

Response to Letter to the Editor From Malozowski: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”

por Thornton, Paul S, Maniatis, Aristides K, Aghajanova, Elena, Chertok, Elena, Lin, Zhengning, Song, Wenjie, Christoffersen, Eva Dam, Breinholt, Vibeke Miller, Giorgadze, Elene, Korpal-Szczyrska, Maria, Hofman, Paul L, Karpf, David B, Shu, Aimee D, Beckert, Michael
Publicado 2021

Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial

por Maniatis, Aristides K., Nadgir, Ulhas, Saenger, Paul, Reifschneider, Kent L., Abuzzahab, Jennifer, Deeb, Larry, Fox, Larry A., Woods, Katie A., Song, Wenjie, Mao, Meng, Chessler, Steven D., Komirenko, Allison S., Shu, Aimee D., Casella, Samuel J., Thornton, Paul S.
Publicado 2022

SAT-LB16 Maintenance of Favorable Treatment Effect of Once-Weekly TransCon hGH for Children With Growth Hormone Deficiency: Interim Analysis From the Enlighten Long-Term Extension...

por Maniatis, Aristides K, Casella, Samuel J, Nadgir, Ulhas M, Mick, Gail J, Hofman, Paul, Saenger, Paul, Chertok, Elena D, Warshauer, Jeremy, Song, Wenjie, Peng, Jessica M, Komirenko, Allison S, Shu, Aimee D, Beckert, Michael, Aghajanova, Elena M, Thornton, Paul S
Publicado 2020

OR10-05 Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency

por Maniatis, Aristides K, Nadgir, Ulhas, Saenger, Paul, Mick, Gail, Reifschneider, Kent L, Abuzzahab, Mary Jennifer, Deeb, Larry, Fox, Larry A, Woods, Katie A, Peng, Jessica M, Karpf, David B, Shu, Aimee D, Song, Wenjie, Casella, Samuel J, Thornton, Paul S
Publicado 2020

Weekly Lonapegsomatropin in Treatment–Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial

por Thornton, Paul S, Maniatis, Aristides K, Aghajanova, Elena, Chertok, Elena, Vlachopapadopoulou, Elpis, Lin, Zhengning, Song, Wenjie, Christoffersen, Eva Dam, Breinholt, Vibeke Miller, Kovalenko, Tatiana, Giorgadze, Elene, Korpal-Szczyrska, Maria, Hofman, Paul L, Karpf, David B, Shu, Aimee D, Beckert, Michael
Publicado 2021

Response to Letter to the Editor From L. Sävendahl et al: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”

por Thornton, Paul S, Maniatis, Aristides K, Aghajanova, Elena, Chertok, Elena, Vlachopapadopoulou, Elpis, Lin, Zhengning, Song, Wenjie, Christoffersen, Eva Dam, Breinholt, Vibeke Miller, Kovalenko, Tatiana, Giorgadze, Elene, Korpal-Szczyrska, Maria, Hofman, Paul L, Karpf, David B, Shu, Aimee D, Beckert, Michael
Publicado 2021